Agenus | AGEN - Beneficio Bruto En Ventas

Precio De Mercado
4.16
Cambio Diario
0.20 5.05%
Mensual
26.44%
Anual
133.71%
Q2 Expectativa
3.85




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Agenus USD 34.2M 4.61M 2025-12
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Celldex Therapeutics USD 121K 609K 2025-12
CSL USD 4.46B 2.71B 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.39B 118.68M 2025-12
Intrexon USD -297K 167K 2024-06
J&J USD 16.6B 118M 2025-12
Jiangsu Hengrui CNY 6.36B 1.15B 2025-09
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
Merck EUR 2.96B 252M 2025-12
Merck USD 13.42B 431M 2025-09
Novartis USD 10.25B 570M 2025-12
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sangamo BioSciences -2.39M 1.09M 2024-06
Veracyte USD 101.97M 10.69M 2025-12